We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Dasatinibis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Dasatinib studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2015–2022 with a typical study size of 14 participants.
Based on 6 studies · 14 total participants
Confidence
LowBy outcome
Dasatinib has an evidence score of 3.5/10 — emerging evidence based on 6 indexed studies. A leukemia chemotherapy drug (tyrosine-kinase inhibitor) used off-label — combined with quercetin (the 'D+Q' protocol) — as a senolytic to clear senescent 'zombie' cells. Animal data are striking and the first small human pilots are promising, but it is a serious cancer drug with significant toxicity and almost no human longevity evidence. Prescription drug, not a supplement. Representative study: PMID 29988130.
The commonly studied dose of Dasatinib is No validated longevity dose. Senolytic research uses intermittent 'hit-and-run' D+Q (e.g. dasatinib 100 mg + quercetin for ~2–3 days, repeated periodically) — investigational and only appropriate under medical supervision. Approved leukemia dosing is continuous and higher.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Dasatinib (Sprycel) — senolytic use
A leukemia chemotherapy drug (tyrosine-kinase inhibitor) used off-label — combined with quercetin (the 'D+Q' protocol) — as a senolytic to clear senescent 'zombie' cells. Animal data are striking and the first small human pilots are promising, but it is a serious cancer drug with significant toxicity and almost no human longevity evidence. Prescription drug, not a supplement.
Dasatinib (with quercetin) is the founding senolytic with strong animal lifespan/function data and encouraging first-in-human pilots, but human evidence is tiny and mostly open-label with no longevity outcomes, and it is a serious leukemia drug with significant toxicity — so the longevity use is early and high-risk.
Dasatinib is a potent tyrosine-kinase inhibitor FDA-approved to treat chronic myeloid leukemia and Philadelphia-chromosome-positive ALL. In geroscience it is used off-label as a senolytic — a drug that selectively kills senescent ('zombie') cells, which accumulate with age and drive chronic inflammation.
It is almost always paired with the flavonoid quercetin (the 'D+Q' protocol), because dasatinib and quercetin clear different senescent-cell types; quercetin is already a common dietary supplement.
The preclinical case is strong: D+Q improved physical function and extended lifespan in old mice and cleared senescent cells in multiple tissues, and it gave the field its founding senolytic.
Early human translation is genuinely promising but very preliminary: a first-in-human open-label pilot in idiopathic pulmonary fibrosis reported improved physical function, and a small clinical-trial report showed D+Q reduced senescent-cell markers in tissue from people with diabetic kidney disease.
The honest reality is that these are tiny, short, mostly open-label studies with no longevity outcomes, and dasatinib itself is a serious oncology drug: it carries risks of myelosuppression, bleeding, fluid retention/pleural effusions, QT prolongation, and cardiac effects, and has major drug interactions.
Senolytic protocols use intermittent 'hit-and-run' dosing (a few days, periodically) to limit exposure, but the right human dose/schedule for longevity is unknown. This is a prescription chemotherapy agent used off-label, not a supplement, and self-experimentation is risky.
The score reflects compelling preclinical senolytic data and encouraging early pilots against minimal human evidence and a serious toxicity profile.
Dasatinib disables the pro-survival ('SCAP') pathways senescent cells depend on, triggering their apoptosis. Paired with quercetin to cover complementary senescent-cell types.
Its broad TKI activity (BCR-ABL, SRC family, ephrin receptors) underlies both the senolytic effect and the systemic toxicity.
Clearing senescent cells lowers the senescence-associated secretory phenotype — the chronic inflammatory signaling implicated in aging.
How Dasatinib works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated longevity dose. Senolytic research uses intermittent 'hit-and-run' D+Q (e.g. dasatinib 100 mg + quercetin for ~2–3 days, repeated periodically) — investigational and only appropriate under medical supervision. Approved leukemia dosing is continuous and higher.
Loading: No loading; senolytic protocols dose intermittently for a few days at a time rather than continuously.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral dasatinib + quercetin (D+Q) | Recommended |
| 💊Fisetin (a gentler dietary senolytic alternative) | Alternative |
Pharmaceutical dasatinib only, under supervision; grey-market sourcing of a toxic oncology drug is dangerous.
Compare Dasatinib vs Fisetin →Minimum: 1 weeks
Optimal: 4 weeks
Cycling: Senolytic 'hit-and-run': short intermittent courses (days, repeated every few weeks/months) rather than continuous dosing, to clear senescent cells while limiting exposure. The optimal human schedule is unknown.
Note: Intermittent senolytic dosing (a few days periodically). Avoid antacids, grapefruit, and CYP3A4 inhibitors.
Dose-response data unavailable. The current published research for Dasatinib does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
D+Q improved physical function and extended lifespan in old mice — not shown in humans.
Small pilots reduced senescent-cell markers and improved physical function in specific patient groups.
Myelosuppression, bleeding, fluid retention/pleural effusions, QT prolongation, and cardiac effects — serious risks of a leukemia drug.
Contraindicated — cytotoxic, teratogenic potential.
Avoid or use with great caution — additive bleeding risk.
Avoid — risk of effusions and arrhythmia.
Strong inhibitors (ketoconazole, grapefruit) raise dasatinib toxicity; inducers (rifampin) reduce efficacy.
Markedly reduce dasatinib absorption.
Dasatinib inhibits platelet function — additive bleeding risk.
Tip: A hallmark oncology toxicity; relevant mainly to continuous dosing, less to brief senolytic courses — but monitor.
Tip: Characteristic dasatinib effect; seek care for shortness of breath.
Tip: Platelet inhibition; caution with anticoagulants.
Tip: Avoid with other QT-prolonging drugs or cardiac disease.
Timing is flexible for Dasatinib — consistent daily use matters more than the time of day. Avoid acid reducers (they cut absorption) and grapefruit/CYP3A4 inhibitors (which raise levels).
Dasatinib should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are myelosuppression (low blood counts), fluid retention / pleural effusion, bleeding / bruising. Use caution if any of these apply to you: Pregnancy / breastfeeding; Active bleeding or significant thrombocytopenia; Significant cardiac disease / QT prolongation.
Fermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.